Keymed Biosciences (2162.HK) traded up 3.22 % during a 24 hours period ending at 10:39 PM Central Europe on Monday 26th. One Keymed Biosciences stock can currently be bought for about HKD 81 on popular exchanges. Current supply of Keymed Biosciences stocks is 294.5 mn. Keymed Biosciences has a current market capitalization of HKD 24.1 bn and approximately HKD 201.7 mn worth of Keymed Biosciences was traded on exchanges in the last 24 hours. Since last month end, Keymed Biosciences has traded 10.26 % up. Simple moving average of last 200 days is at HKD 68.3. The highest price of past 52 weeks was recorded at HKD 89.75 on 07/07/2026. 52 weeks low was at HKD 44.66 on 03/04/2026.
Here is how related stocks have performed in the past 24 hours:
Jointown Pharmaceutical (600998.SS) traded flat 0 % and now trades at CNY 5.12. Jointown Pharmaceutical has a market capitalisation of CNY 24.4 bn. Current price/earnings ratio for Jointown Pharmaceutical is 12.68. Jointown Pharmaceutical, a listed entity in the Chinese market, was mentioned among a group of stocks that crossed their annual moving averages during the trading session. The firm’s shares, alongside other healthcare names such as Baoyang Pharmaceutical and Shijian Pharmaceutical, experienced notable movements in the afternoon, reflecting broader activity in the medical sector. No specific details regarding earnings, dividends, or strategic initiatives for Jointown Pharmaceutical were provided in the available excerpts. The market context for the day included a modest overall decline in the Shanghai Composite Index, with the healthcare and consumer segments showing resilience, while technology and hardware stocks faced weakness. The reporting focuses on market dynamics and sector performance rather than individual corporate announcements.
Fulin Precision (300432.SZ) traded flat 0 % and now trades at CNY 14. Current market capitalisation for Fulin Precision is CNY 24.1 bn. Current price/earnings ratio for Fulin Precision is 45.08. FULIN PRECISION CO LTD reported a robust performance for the first three quarters, with operating revenue doubling year‑over‑year and net profit similarly rising. The company highlighted that the substantial growth stemmed largely from its lithium‑ion positive‑electrode material business. Quarterly results showed a significant uptick in the third quarter, where revenue climbed over 120 percent and net profit surged more than 140 percent compared with the prior period. The overall trend suggests that the firm’s expansion in key product segments is translating into strong profitability gains, reinforcing its position in the competitive market.
Beijing Tiantan Biological (600161.SS) traded flat 0 % and now trades at CNY 12.62. Beijing Tiantan Biological has a market capitalisation of CNY 24.2 bn. Current price/earnings ratio for Beijing Tiantan Biological is 32.06.
Lyc (301699.SZ) traded flat 0 % and now trades at CNY 33.9. Current market capitalisation for Lyc is CNY 24.2 bn.
Hubei Jumpcan Pharmaceut (600566.SS) traded flat 0 % and now trades at CNY 26.62. Current market capitalisation for Hubei Jumpcan Pharmaceut is CNY 24.3 bn. Hubei Jumpcan Pharmaceut has a current price to earnings ratio of 13.2.
About Keymed Biosciences
Keymed Biosciences Inc. is a biotechnology company operating in China with its base in Chengdu. The company is focused on in-house discovery and development of innovative biological therapies. Keymed Biosciences provides services in China.